Notably, unlike β-catenin and APC mutations in colon cancer, these mutations are very rare in NSCLC20, 21; thus, understanding the biological basis for the observed deregulation of Wnt overactivation is of great value for future development of novel therapeutic strategies. This evidence concerns the gene APC and colonic neoplasm.